NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $293,032 | -29.4% | 7,061 | +2.3% | 0.20% | -30.2% |
| Q1 2023 | $415,026 | -25.6% | 6,901 | -9.2% | 0.28% | -31.3% |
| Q4 2022 | $557,753 | +3.1% | 7,604 | +6.9% | 0.41% | -7.3% |
| Q3 2022 | $541,000 | +9.1% | 7,116 | -0.2% | 0.44% | +8.1% |
| Q2 2022 | $496,000 | -13.7% | 7,132 | +2.7% | 0.41% | -16.9% |
| Q1 2022 | $575,000 | -16.1% | 6,943 | -28.9% | 0.49% | -11.4% |
| Q4 2021 | $685,000 | – | 9,767 | – | 0.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |